File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)

Article: Galectin-3 and risk of cardiovascular events and all-cause mortality in type 2 diabetes

TitleGalectin-3 and risk of cardiovascular events and all-cause mortality in type 2 diabetes
Authors
Issue Date2019
PublisherJohn Wiley & Sons Ltd. The Journal's web site is located at http://onlinelibrary.wiley.com/journal/10.1002/(ISSN)1520-7560
Citation
Diabetes/Metabolism Research and Reviews, 2019, v. 35 n. 2, p. e3093 How to Cite?
AbstractAIMS: Recent clinical studies have shown that galectin-3 is a prognostic indicator in patients with coronary heart disease and in patients with heart failure. Experimental data suggest that galectin-3 may play a role in atherogenesis. We have evaluated whether serum galectin-3 level is associated with cardiovascular outcome in type 2 diabetes. MATERIALS AND METHODS: Galectin-3 was measured in baseline samples in 1495 persons with type 2 diabetes. The primary cardiovascular outcome, incident cardiovascular events, was defined as first non-fatal myocardial infarction, non-fatal stroke, coronary revascularization, or death from cardiovascular cause. The secondary outcome was all-cause mortality. RESULTS: At baseline, 12% of the subjects had prevalent cardiovascular disease. Serum galectin-3 was increased in the group with incident cardiovascular events compared with those who remained free of events during follow up (9.03 +/- 2.98 ng/mL vs 8.15 +/- 2.76, P < 0.01). Serum galectin-3 was also significantly increased in those subjects with a fatal outcome. The hazard ratios (HR) for cardiovascular events and all-cause mortality for individuals in the top quartile were 2.50 (95% CI 1.87, 3.36, P < 0.001) and 3.92 (95%CI 2.55, 6.01, P < 0.001), respectively. In a multivariate Cox regression analysis including traditional risk factors, log (eGFR), baseline albuminuria, and cardiovascular disease status, the HR per standard deviation change in galectin-3 was 1.13 (95% CI 1.02, 1.26, P = 0.02) for cardiovascular events and 1.17 (95% CI 1.01, 1.35, P = 0.04) for all-cause mortality. CONCLUSIONS: Serum galectin-3 is associated with adverse cardiovascular outcomes in persons with type 2 diabetes independent of traditional risk factors.
Persistent Identifierhttp://hdl.handle.net/10722/269435
ISSN
2017 Impact Factor: 3.904
2015 SCImago Journal Rankings: 1.617

 

DC FieldValueLanguage
dc.contributor.authorTan, KCB-
dc.contributor.authorCheung, CL-
dc.contributor.authorLee, CHA-
dc.contributor.authorLam, JKY-
dc.contributor.authorWong, Y-
dc.contributor.authorShiu, SWM-
dc.date.accessioned2019-04-24T08:07:39Z-
dc.date.available2019-04-24T08:07:39Z-
dc.date.issued2019-
dc.identifier.citationDiabetes/Metabolism Research and Reviews, 2019, v. 35 n. 2, p. e3093-
dc.identifier.issn1520-7560-
dc.identifier.urihttp://hdl.handle.net/10722/269435-
dc.description.abstractAIMS: Recent clinical studies have shown that galectin-3 is a prognostic indicator in patients with coronary heart disease and in patients with heart failure. Experimental data suggest that galectin-3 may play a role in atherogenesis. We have evaluated whether serum galectin-3 level is associated with cardiovascular outcome in type 2 diabetes. MATERIALS AND METHODS: Galectin-3 was measured in baseline samples in 1495 persons with type 2 diabetes. The primary cardiovascular outcome, incident cardiovascular events, was defined as first non-fatal myocardial infarction, non-fatal stroke, coronary revascularization, or death from cardiovascular cause. The secondary outcome was all-cause mortality. RESULTS: At baseline, 12% of the subjects had prevalent cardiovascular disease. Serum galectin-3 was increased in the group with incident cardiovascular events compared with those who remained free of events during follow up (9.03 +/- 2.98 ng/mL vs 8.15 +/- 2.76, P < 0.01). Serum galectin-3 was also significantly increased in those subjects with a fatal outcome. The hazard ratios (HR) for cardiovascular events and all-cause mortality for individuals in the top quartile were 2.50 (95% CI 1.87, 3.36, P < 0.001) and 3.92 (95%CI 2.55, 6.01, P < 0.001), respectively. In a multivariate Cox regression analysis including traditional risk factors, log (eGFR), baseline albuminuria, and cardiovascular disease status, the HR per standard deviation change in galectin-3 was 1.13 (95% CI 1.02, 1.26, P = 0.02) for cardiovascular events and 1.17 (95% CI 1.01, 1.35, P = 0.04) for all-cause mortality. CONCLUSIONS: Serum galectin-3 is associated with adverse cardiovascular outcomes in persons with type 2 diabetes independent of traditional risk factors.-
dc.languageeng-
dc.publisherJohn Wiley & Sons Ltd. The Journal's web site is located at http://onlinelibrary.wiley.com/journal/10.1002/(ISSN)1520-7560-
dc.relation.ispartofDiabetes/Metabolism Research and Reviews-
dc.rightsThis is the peer reviewed version of the following article: [FULL CITE], which has been published in final form at [Link to final article using the DOI]. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Use of Self-Archived Versions.-
dc.titleGalectin-3 and risk of cardiovascular events and all-cause mortality in type 2 diabetes-
dc.typeArticle-
dc.identifier.emailTan, KCB: kcbtan@hkucc.hku.hk-
dc.identifier.emailCheung, CL: lung1212@hku.hk-
dc.identifier.emailLee, CHA: achlee@hku.hk-
dc.identifier.emailWong, Y: ywong@hku.hk-
dc.identifier.emailShiu, SWM: swmshiu@hku.hk-
dc.identifier.authorityTan, KCB=rp00402-
dc.identifier.authorityCheung, CL=rp01749-
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1002/dmrr.3093-
dc.identifier.hkuros297361-
dc.identifier.volume35-
dc.identifier.issue2-
dc.identifier.spagee3093-
dc.identifier.epagee3093-
dc.publisher.placeUnited Kingdom-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats